Since regorafenib is also an FDA-approved drug for colorectal cancer treatment [38,39], and according to our data another potential candidate for treatment based on BCL-xL antagonism, we also analyzed BCL-xL levels in this tumor category (Figure 8F). This evidence concerns the gene BCL2L1 and colorectal cancer.